Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)
- Groot, S. de
- Charehbili, A.
- Laarhoven, H.W.M. van
- Mooyaart, A.L.
- Dekker-Ensink, N.G.
- Ven, S. van de
- Janssen, L.G.
- Swen, J.J.
- Smit, V.T.
- Heijns, J.B.
- Kessels, L.W.
- Straaten, T. van der
- Bohringer, S.
- Gelderblom, H.
- Hoeven, J.J. van der
- Guchelaar (LUMC), H.J.
- Pijl, H.
- Kroep, J.R.
DOIAbstract
BACKGROUND: The insulin-like growth factor 1 (IGF-1) pathway is involved in cell growth and proliferation and is associated with tumorigenesis and therapy resistance. This study aims to elucidate whether variation in the IGF-1 pathway is predictive for pathologic response in early HER2 negative breast cancer (BC) patients, taking part in the phase III NEOZOTAC trial, randomizing between 6 cycles of neoadjuvant TAC chemotherapy with or without zoledronic acid. METHODS: Formalin-fixed paraffin-embedded tissue samples of pre-chemotherapy biopsies and operation specimens were collected for analysis of IGF-1 receptor (IGF-1R) expression (n = 216) and for analysis of 8 candidate single nucleotide polymorphisms (SNPs) in genes of the IGF-1 pathway...
Add to ORKG